The world's leading journal on infectious diseases. Clinical ID, public health, microbiology, and everything in-between. Official publication of @IDSAinfo
A randomized controlled trial of cefiderocol versus standard therapy for Gram-negative bacterial bloodstream infections: Benefit and risk assessment using DOOR and generalized pairwise comparisons
π Repost
bit.ly/4A81vS4
Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial
β Just Accepted
bit.ly/4jkAa9d
π¨New in CID: A new article series explores recent advances in point-of-care testing that address the need for more rapid, accessible and accurate infectious diseases diagnostics.
Read more: bit.ly/41hmOjx
Safety of tuberculosis preventive treatment among people receiving or about to initiate immunosuppressive medications: a systematic review and meta-analysis
β Just Accepted
π bit.ly/4xCB6Jq
Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial
β Just Accepted
β Editor's Choice
π bit.ly/4iF8jAi
Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial
π Repost
β Editor's Choice
π bit.ly/4zVjnzw
A Multistate Investigation of Serious Adverse Events, including Deaths, following Ceftriaxone Injections, September 2024βAugust 2025
π Repost
π bit.ly/4gDhEat
π¨New in CID: A new article series explores recent advances in point-of-care testing that address the need for more rapid, accessible and accurate infectious diseases diagnostics.
Read more: bit.ly/41hmOjx